Early Phase Clinical Trials: Canada

Rolling applications

Funding for clinical trials and clinical trial sub-studies that accelerate the development of therapeutics for neurodegenerative diseases of aging

Maximum $1,500,000 over up to 4 years

CONTINUING FOR 2020

- Complementary approaches such as diet, physical activity, sleep, nutritional supplements, speech therapy, and cognitive therapy are eligible

ELIGIBILITY CRITERIA

Principal applicant must be:
1. A researcher currently working in Canada at least 30% of the time
2. At or above the level of Assistant Professor or equivalent
3. Affiliated with a Canada Revenue Agency-qualified donee institution located in Canada

Project must be:
1. A clinical trial(s) and/or a clinical trial sub-study(s) that accelerates the development of therapeutics for neurodegenerative diseases of aging
2. The development of a therapeutic, tool, and/or complementary approaches

INSTITUTE DEFINITION OF NEURODEGENERATIVE DISEASES OF AGING

- Alzheimer’s disease
- Dementia with Lewy bodies
- Frontotemporal dementia
- Multiple system atrophy
- Parkinson’s disease
- Progressive supranuclear palsy
- Vascular contributions to the above
- Prodromes to the above

APPLICATION PROCESS

1. Review all program information and determine whether your project is in scope
2. Register or sign in to our online grants management system
3. Complete and submit a Letter of Intent (LOI)
   - If selected, applicants will be invited to submit a full Proposal
   - Applicants can expect to receive the outcome of their LOI application within ~2 months of submission
4. Complete and submit a full Proposal (by invite only)

FOR MORE INFORMATION

www.westonbraininstitute.ca/early-phase-clinical-trials-canada
416-967-7979 | info@westonbrain.org